Restriction of DNA viruses by TRIM5a and ZAP / TRIM25 / KHNYN: mechanisms of restriction and viral evasion

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:5 publications

Grant number: MR/W025590/1

Grant search

Key facts

  • Disease

    Vaccinia virus infection, Smallpox
  • Start & end year

    2023
    2025
  • Known Financial Commitments (USD)

    $797,341.35
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    Professor Geoffrey Smith
  • Research Location

    United Kingdom
  • Lead Research Institution

    University of Oxford
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

  • Mpox Research Priorities

    Pathogen: natural history, transmission and diagnostics

  • Mpox Research Sub Priorities

    Research for enhanced understanding of the disease

Abstract

The host restriction factors TRIM5a, ZAP, TRIM25 and KHNYN provide defense against RNA viruses. For instance, TRIM5a provides protection against different retroviruses, including HIV. Proteins ZAP, TRIM25 and KHNYN, which show some functional interdependence, are also active against RNA viruses with CpG rich genomes and recently, ZAP and TRIM25 were shown to also restrict human cytomegalovirus (HCMV). We discovered that vaccinia virus (VACV) infection induce degradation of all 4 cellular proteins, and so hypothesised that they may have anti-VACV activity. This hypothesis was proved correct, for cells lacking TRIM5a, ZAP, TRIM25 or KHNYN individually, supported enhanced VACV replication, showing these proteins do provide defense against this large DNA virus. Like HIV, VACV virions also package cyclophilin A and VACV replication is inhibited by cyclosporine A in a TRIM5-dependent way. Loss of TRIM5a also enhanced herpes simplex virus (HSV) 1 replication. The project will investigate how these host proteins restrict VACV replication and how VACV evades such restriction. What viral proteins do they bind to? At what stage is virus replication restricted? Is this a direct effect following recognition of specific virus components, or indirect, by activation of the innate immunity by these restriction factors? We will also test if these host proteins can restrict the replication of other dsDNA viruses, such as HSV-1 and HCMV, and, for TRIM5a, monkeypox virus and variola virus. In parallel, the VACV protein(s) that induce the degradation of these cellular proteins will be identified, where not known already, and then their mechanism(s) of action will be studied. Can they act independently? Since the degradation of these cellular proteins is proteasome-dependent, it suggests these proteins may be ubiquitylated by E3 ubiquitin ligases and thereby marked for destruction. Which E3 ligases or other factors are involved?

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

HDAC5 enhances IRF3 activation and is targeted for degradation by protein C6 from orthopoxviruses including Monkeypox virus and Variola virus.

Filamin B restricts vaccinia virus spread and is targeted by vaccinia virus protein C4.

The SARS-CoV-2 protein ORF3c is a mitochondrial modulator of innate immunity.

ICTV Virus Taxonomy Profile: <i>Poxviridae</i> 2023.

Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.